Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop better ways to treat liver cancer, known as
hepatocellular carcinoma or HCC, while it is still in the liver. Many treatments exist to
treat tumors in the liver when they are small but after they grow past a certain size, local
therapies such as surgery, Trans-Arterial Chemo Embolization (TACE), or Radiofrequency
Ablation (RFA) are not effective. The purpose of this study to test the combination of two
known treatments - TACE and Stereotactic Body Radiation Therapy (SBRT) - to be used together
to treat larger or difficult to access liver tumors. Each treatment has been shown to work
well but has limitations. The study will combine the treatments in an organized sequence and
monitor closely how effective this combination controls tumors.